SAFETY DATA SHEET



1. Identification

Product identifier Bebtelovimab Injection

Other means of identification

Item Code VL7589, 703370, CT9588, 703230

LY Number LY3853113 Recommended use Pharmaceutical **Recommended restrictions** None known.

Manufacturer/Importer/Supplier/Distributor information

Manufacturer

Eli Lilly and Company Company name Lilly Corporate Center **Address** Indianapolis, IN 46285

United States

Phone: Telephone +1-317-276-2000

E-mail lilly_sds@lilly.com

CHEMTREC: **Emergency phone number** +1-800-424-9300

2. Hazard(s) identification

Not classified. Physical hazards Not classified. **Health hazards OSHA** defined hazards Not classified.

Label elements

None. Hazard symbol Signal word None.

Hazard statement The mixture does not meet the criteria for classification.

Precautionary statement

Prevention Not available. Response Not available. Not available. Storage Not available. **Disposal** Hazard(s) not otherwise None known.

classified (HNOC)

3. Composition/information on ingredients

Mixtures

Chemical name	Common name and synonyms	CAS number	%
Bebtelovimab		2578319-11-4	7 - 9

Remaining components of this product are non-hazardous and/or are present at concentrations Composition comments

below reportable levels.

4. First-aid measures

Call a physician if symptoms develop or persist. Inhalation

Rinse skin with water/shower. Get medical attention if irritation develops and persists. Skin contact

Eye contact Rinse with water. Get medical attention if irritation develops and persists.

Ingestion Get medical attention if symptoms occur.

Most important

characteristics of monoclonal antibodies, this substance/preparation is considered unlikely to symptoms/effects, acute and produce health effects through relevant routes of occupational exposures. delayed

Material name: Bebtelovimab Injection SDS US 1/5

This substance is a monoclonal antibody. Based on the biophysical properties and absorption

7598 Version #: 02 Revision date: 08-31-2021 Issue date: 08-31-2021

Indication of immediate medical attention and special treatment needed

None known.

5. Fire-fighting measures

Suitable extinguishing media

Unsuitable extinguishing

media

None known.

Specific hazards arising from

the chemical

Not applicable.

Special protective equipment

and precautions for firefighters

Wear suitable protective equipment.

General fire hazards

This product is an aqueous mixture which will not burn.

6. Accidental release measures

Personal precautions. protective equipment and emergency procedures

Avoid inhalation of mists or aerosols.

Methods and materials for containment and cleaning up Use absorbent/adsorbent material to solidify liquids. Clean up promptly by sweeping or vacuum.

Wear appropriate protective equipment and clothing during clean-up.

Use fire-extinguishing media appropriate for surrounding materials.

Avoid release to the environment. **Environmental precautions**

7. Handling and storage

Precautions for safe handling

Avoid breathing mist or vapor. Avoid contact with eyes, skin, and clothing. See Section 8 of the

SDS for Personal Protective Equipment.

Conditions for safe storage, including any incompatibilities Keep container tightly closed in a dry and well-ventilated place.

8. Exposure controls/personal protection

Occupational exposure limits

This mixture has no ingredients that have PEL, TLV, or other recommended exposure limit.

Biological limit values Exposure guidelines

No biological exposure limits noted for the ingredient(s). Occupational Exposure Limit (OEL): Not established

Preliminary guidance: Control exposures to between 20 ug/m3 and 100 ug/m3 until an OEL is

established. (Bebtelovimab)

Appropriate engineering

controls

Contained handling practices preferred. If open handling is necessary, use control measures (i.e. ventilated enclosure, local exhaust ventilation) to maintain airborne levels below the occupational

exposure level (OEL).

Individual protection measures, such as personal protective equipment

Eye/face protection

Safety glasses with side shields recommended. If splash potential or dusty operations, wear

goggles/faceshield.

Skin protection

Hand protection

Chemical resistant gloves.

Other

While monoclonal antibodies are not anticipated to be readily absorbed through the skin, wear

impervious gloves and body covering (i.e. lab coat) to minimize skin contact.

Respiratory protection

If the applicable occupational exposure level (OEL) is anticipated to be exceeded, wear an

approved respirator with sufficient protection factor to control exposure below the OEL.

General hygiene considerations

Engineering controls should be used as the primary means to control workplace exposures. Follow good workplace hygiene practices such as washing hands after handling this material.

This substance is a monoclonal antibody. Based on the biophysical properties and absorption characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered occupationally relevant and potential bioavailability through inhalation is minimal.

9. Physical and chemical properties

Appearance

Physical state Liquid.

Form Aqueous Solution

Colorless. Color Odorless Odor

Material name: Bebtelovimab Injection 2/5

Not available. **Odor threshold**

Ha

Melting point/freezing point Not available. Initial boiling point and boiling Not available.

range

Not available. Flash point **Evaporation rate** Not available. Flammability (solid, gas) Not applicable. Upper/lower flammability or explosive limits

Explosive limit - lower (%) Not available. Not available. Explosive limit - upper (%) Not available. Vapor pressure Not available. Vapor density Not available. Relative density

Solubility(ies)

Soluble Solubility (water)

Partition coefficient Not available.

(n-octanol/water)

Auto-ignition temperature Not available. Not available. **Decomposition temperature** Not available. **Viscosity**

Other information

Not explosive. **Explosive properties**

Oxidizing properties No oxidizing properties.

10. Stability and reactivity

Reactivity Not water reactive.

Material is stable under normal conditions. **Chemical stability** Possibility of hazardous Hazardous polymerization does not occur.

reactions

Conditions to avoid None under normal conditions.

Incompatible materials Strong oxidizing agents.

Hazardous decomposition

products

No hazardous decomposition products are known.

11. Toxicological information

Information on toxicological effects

Based on available data, the classification criteria are not met. **Acute toxicity** Based on available data, the classification criteria are not met. Skin corrosion/irritation Based on available data, the classification criteria are not met. Serious eye damage/eye

irritation

Respiratory or skin sensitization

Respiratory sensitization Due to inconclusive data the classification criteria are not met. Skin sensitization Due to inconclusive data the classification criteria are not met.

This substance is a monoclonal antibody. It does not possess mutagenic potential. Germ cell mutagenicity

Mutagenicity testing has not been conducted.

Carcinogenicity Not listed by IARC, NTP, ACGIH or OSHA.

Based on available data, the classification criteria are not met.

IARC Monographs. Overall Evaluation of Carcinogenicity

7598 Version #: 02 Revision date: 08-31-2021 Issue date: 08-31-2021

Not listed.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Not listed.

Material name: Bebtelovimab Injection

SDS US

US. National Toxicology Program (NTP) Report on Carcinogens

Not listed.

Based on available data, the classification criteria are not met. Reproductive toxicity

Specific target organ toxicity -

single exposure

Based on available data, the classification criteria are not met.

Specific target organ toxicity -

repeated exposure

No significant target organ toxicity reported. (Injection) (Bebtelovimab)

Based on available data, the classification criteria are not met.

Based on available data, the classification criteria are not met. **Aspiration hazard**

This substance is a monoclonal antibody. Based on the biophysical properties and absorption **Further information**

characteristics of monoclonal antibodies, oral and dermal routes of exposure are not considered

occupationally relevant and potential bioavailability through inhalation is minimal.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Not available. Persistence and degradability Not available. Bioaccumulative potential Not available. Mobility in soil Other adverse effects Not available.

13. Disposal considerations

Disposal instructions Dispose in accordance with all applicable regulations.

14. Transport information

DOT

Not regulated as dangerous goods.

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to

Not applicable.

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

US federal regulations This product is not known to be a "Hazardous Chemical" as defined by the OSHA Hazard

Communication Standard, 29 CFR 1910.1200.

Toxic Substances Control Act (TSCA)

TSCA Section 12(b) Export Notification (40 CFR 707, Subpt. D)

Not regulated.

CERCLA Hazardous Substance List (40 CFR 302.4)

Not listed.

SARA 304 Emergency release notification

Not regulated.

OSHA Specifically Regulated Substances (29 CFR 1910.1001-1053)

Superfund Amendments and Reauthorization Act of 1986 (SARA)

7598 Version #: 02 Revision date: 08-31-2021 Issue date: 08-31-2021

SARA 313 (TRI reporting)

Not regulated.

Other federal regulations

Clean Air Act (CAA) Section 112 Hazardous Air Pollutants (HAPs) List

Not regulated.

Clean Air Act (CAA) Section 112(r) Accidental Release Prevention (40 CFR 68.130)

Not regulated.

Safe Drinking Water Act Not regulated.

(SDWA)

Material name: Bebtelovimab Injection

International Inventories

Country(s) or regionInventory nameOn inventory (yes/no)*CanadaDomestic Substances List (DSL)No

Canada Non-Domestic Substances List (NDSL) No

United States & Puerto Rico Toxic Substances Control Act (TSCA) Inventory

*A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s)

A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information, including date of preparation or last revision

 Issue date
 08-31-2021

 Revision date
 08-31-2021

Version # 02

List of abbreviations ACGIH: American Conference of Governmental Industrial Hygienists.

DOT: Department of Transportation (49 CFR 172.101). IARC: International Agency for Research on Cancer.

IATA: International Air Transport Association.

IMDG Code: International Maritime Dangerous Goods Code.

MARPOL: International Convention for the Prevention of Pollution from Ships.

NIOSH: National Institute for Occupational Safety & Health. OSHA: Occupational Safety & Health Administration.

PEL: Permissible Exposure Limit.

RID: Regulations concerning the international carriage of dangerous goods by rail (Règlement International concernant le transport de marchandises dangereuses par chemin de fer).

TLV: Threshold Limit Value.

Disclaimer As of the date of issuance, we are providing available information relevant to the handling of this

material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANT ABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately

trained personnel. Nor is this safety data sheet intended to be a substitute for product literature

which may accompany the finished product.

For additional information contact:

Eli Lilly and Company Hazard Communication +1-317-651-9533

Revision information Product and Company Identification: Eli Lilly Info

Physical & Chemical Properties: Multiple Properties

Other information, including date of preparation or last revision: Disclaimer

Material name: Bebtelovimab Injection

7598 Version #: 02 Revision date: 08-31-2021 Issue date: 08-31-2021 5 / 5

Nο